ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1135

Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis

Jose R. Provenza1, Samuel K. Shinjo2, Joyce M. Silva3, Carla RGS. Peron4 and Francisco AC Rocha5, 1Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Clinical Research, Sao Paulo, Brazil, 4Clinical Research, Laboratórios Aché Ltda, Sao Paulo, Brazil, 5Rheumatology, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chondroitin, Glucosamine, Knee, osteoarthritis and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: The analgesic efficacy of combined glucosamine and chondroitin sulfate (CS) in knee osteoarthritis (OA) remains controversial. Criticism to previous studies includes small sample size, short term evaluation and lack of intent-to-treat (ITT) analysis. Glucosamine sulfate (GS) or hydrochloride (GH) formulations and dosing schedule relevance are also not clearly defined.

Methods: 1,120 subjects with radiographic knee OA (Kellgren/Lawrence grades 2-3) and moderate-severe knee pain flare after analgesic washout were randomized (1:1:1) at 16 centers in Brazil to receive GS 500mg/CS 400mg three times daily capsules (GI) or once daily sachet (GII), or GH 500mg/CS 400mg three times daily capsules (GIII) for a 16 week trial. Acetaminophen up to 3,750mg daily was a rescue medication. Primary outcome (ITT) was patient reported pain intensity in the affected knee and variation of Lequesne’s index (LI) at 16 weeks. Monthly secondary outcomes were mean changes from baseline in patient reported pain and LI, patient and physician global assessments of disease activity, acetaminophen consumption, and adherence. Sample size calculation considered a non-inferiority evaluation allowing a difference of less than 1.7 points in the LI and a decrease of pain less than 18mm in GI and GII, as compared to GIII. Safety evaluations were done at each monthly visit.

Results: The ITT population comprised 302, 301, and 306 patients in GI, GII and GIII, respectively, and 911 patients for safety. Demographic data were equally comparable in all groups. The criterion for non-inferiority analysis of GI and GII in relation to GIII, based on confidence interval (95%), was met for pain intensity and LI. The mean of pain reduction (GI: -30.9±1.5; GII: -28.7±1.5; GIII: -29.7±1.5 mm) was significant for all groups at week 16 (P<0.001). Similarly, the mean of LI decrease was significant in all groups (GI: -3.8±0.2; GII: -3.7±0.2; GIII: -3.9±0.2) (P<0.001). Moreover, reduction of acetaminophen consumption (-5, -3, and -5 weekly tablets for GI, GII, and GIII, respectively) was also significant in all groups (P<0.005). Withdrawal rate was 18.2%, 19.3%, and 19.3% for GI, II, and III. Patients that did not complete the study were 77 (44.8%) for lack of adherence, 16 (9.3%) consent withdrawal, 11 (6.4%) adverse events, 8 (4.7%) lost to follow-up, and 17 (9.9%) for other causes.

Conclusion: This is the largest study showing that GS/CS and GH/CS provide clinically meaningful and sustained analgesia in knee OA regardless of dose fractionation. GS/CS (capsule or sachet) and GH/CS formulations are equally effective and safe to treat symptomatic knee OA.


Disclosure:

J. R. Provenza,
None;

S. K. Shinjo,

Federico Foundation,

2;

J. M. Silva,
None;

C. R. Peron,
None;

F. A. Rocha,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combined-glucosamine-and-chondroitin-sulfate-once-of-three-times-daily-provide-clinically-relevant-analgesia-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology